| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ORM; AGP1; AGP-A |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ORM1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SF3A3抗体的3篇参考文献(示例为模拟生成内容，实际文献需根据具体数据库检索)：
1. **文献名称**：*SF3A3 regulates the assembly and function of the spliceosome in human cells*
**作者**：Wang, L. et al.
**摘要**：通过Western blot和免疫荧光技术，利用SF3A3抗体研究其在剪接体动态组装中的作用，发现SF3A3缺失导致pre-mRNA剪接异常。
2. **文献名称**：*Dysregulation of spliceosomal proteins in cancer: SF3A3 as a potential biomarker*
**作者**：Zhang, Y. et al.
**摘要**：该研究使用SF3A3抗体对多种癌症组织进行免疫组化分析，发现SF3A3在肿瘤中高表达，提示其可能作为癌症诊断标志物。
3. **文献名称**：*Proteomic analysis of SF3A3-containing complexes by co-immunoprecipitation*
**作者**：Smith, J. et al.
**摘要**：通过SF3A3抗体进行免疫共沉淀，结合质谱技术鉴定其相互作用蛋白，揭示了SF3A3在剪接体亚基互作网络中的核心地位。
如需具体文献，建议通过PubMed或Google Scholar以 **"SF3A3 antibody"** 或 **"SF3A3 immunolocalization"** 为关键词检索近年研究。
The SF3A3 antibody targets the SF3A3 protein, a critical component of the spliceosome complex responsible for pre-mRNA splicing. SF3A3 (Splicing Factor 3A Subunit 3) is part of the SF3A complex, which, along with SF3B, forms the U2 small nuclear ribonucleoprotein (snRNP) involved in recognizing branch site sequences during spliceosome assembly. This protein plays a vital role in maintaining splicing accuracy and regulating alternative splicing events, impacting gene expression diversity.
Antibodies against SF3A3 are widely used in research to study spliceosome dynamics, RNA processing mechanisms, and diseases linked to splicing dysregulation, such as cancers or neurodegenerative disorders. They enable detection of SF3A3 expression via techniques like Western blotting, immunofluorescence, or immunoprecipitation, helping to elucidate its localization, interactions, or expression levels under various conditions.
Many commercial SF3A3 antibodies are generated using recombinant proteins or peptide immunogens, with validation including specificity tests (e.g., siRNA knockdown or knockout controls) and cross-reactivity checks. Reliable antibodies are essential for investigating how SF3A3 mutations or dysregulation contribute to splicing errors and disease pathogenesis. Additionally, they support drug discovery efforts targeting spliceosome components, particularly in cancers where spliceosome inhibitors are being explored as therapies.
×
